Bioavailability and efficiency of rutin as an antioxidant

a human supplementation study

S P Boyle, V L Dobson, Susan Joyce Duthie, D C Hinselwood, Janet Kyle, A R Collins

Research output: Contribution to journalArticle

127 Citations (Scopus)

Abstract

Objective: To determine the potential antioxidant effect of rutin (quercetin-3-O-beta-rutinoside) supplementation.

Design: A 6-week randomized single-blind placebo controlled trial was conducted; 500 mg rutin supplement was compared to an equivalent amount of glucose placebo. In addition, a pharmacokinetic study was carried out.

Setting: The Rowett Research Institute, Aberdeen, UK.

Subjects: Eighteen healthy non-obese normocholesterolaemic female volunteers in the age range 18-48 y.

Main outcome measures: Plasma flavonoids, ascorbic acid, tocopherols and caratenoids, plasma antioxidant capacity, lymphocyte DNA damage, blood chemistry and haematology, liver function tests, urinary malondialdehyde, 8-hydroxy-2-deoxyguanosine and 8-iso-prostaglandin F-2 alpha.

Results: Eighteen volunteers completed the trial. Rutin supplementation did not induce any adverse changes in blood chemistry or indices of liver function. Plasma flavonoids were significantly elevated in the rutin-supplemented group. Endogenous oxidation of pyrimidines was significantly decreased in both rutin- and placebo-treated volunteers. There was no significant change in the level of urinary 8-hydroxy-2'-deoxyguanosine or urinary malondialdehyde in either group. A linear correlation was observed between urinary malondialdehyde and urinary 8-iso-prostaglandin F-2 alpha (R = 0.54, P < 0.01).

Conclusion: Six weeks' rutin supplementation significantly elevated the levels of three plasma flavonoids (quercetin, kaempferol and isorhamnetin) but there was no significant change in plasma antioxidant status. The decrease in the level of endogenous base oxidation in lymphocyte DNA seen in bath the placeba- and rutin-supplemented subjects may reflect seasonal changes in other dietary antioxidants.

Original languageEnglish
Pages (from-to)774-782
Number of pages9
JournalEuropean Journal of Clinical Nutrition
Volume54
Issue number10
Publication statusPublished - Oct 2000

Keywords

  • flavonoids
  • bioavailability
  • plasma antioxidant status
  • DNA damage
  • 8-iso-prostagiandin F-2 alpha
  • LOW-DENSITY-LIPOPROTEIN
  • CORONARY-HEART-DISEASE
  • PERFORMANCE LIQUID-CHROMATOGRAPHY
  • ARACHIDONIC-ACID METABOLISM
  • LIPID-PEROXIDATION
  • RED WINE
  • IN-VITRO
  • OXIDATIVE MODIFICATION
  • PHENOLIC SUBSTANCES
  • REDUCING ABILITY
  • 8-iso-prostagiandin F-2 alpha

Cite this

Boyle, S. P., Dobson, V. L., Duthie, S. J., Hinselwood, D. C., Kyle, J., & Collins, A. R. (2000). Bioavailability and efficiency of rutin as an antioxidant: a human supplementation study. European Journal of Clinical Nutrition, 54(10), 774-782.

Bioavailability and efficiency of rutin as an antioxidant : a human supplementation study. / Boyle, S P ; Dobson, V L ; Duthie, Susan Joyce; Hinselwood, D C ; Kyle, Janet; Collins, A R .

In: European Journal of Clinical Nutrition, Vol. 54, No. 10, 10.2000, p. 774-782.

Research output: Contribution to journalArticle

Boyle, SP, Dobson, VL, Duthie, SJ, Hinselwood, DC, Kyle, J & Collins, AR 2000, 'Bioavailability and efficiency of rutin as an antioxidant: a human supplementation study', European Journal of Clinical Nutrition, vol. 54, no. 10, pp. 774-782.
Boyle, S P ; Dobson, V L ; Duthie, Susan Joyce ; Hinselwood, D C ; Kyle, Janet ; Collins, A R . / Bioavailability and efficiency of rutin as an antioxidant : a human supplementation study. In: European Journal of Clinical Nutrition. 2000 ; Vol. 54, No. 10. pp. 774-782.
@article{83757fd5905e4866987e08406bef8685,
title = "Bioavailability and efficiency of rutin as an antioxidant: a human supplementation study",
abstract = "Objective: To determine the potential antioxidant effect of rutin (quercetin-3-O-beta-rutinoside) supplementation.Design: A 6-week randomized single-blind placebo controlled trial was conducted; 500 mg rutin supplement was compared to an equivalent amount of glucose placebo. In addition, a pharmacokinetic study was carried out.Setting: The Rowett Research Institute, Aberdeen, UK.Subjects: Eighteen healthy non-obese normocholesterolaemic female volunteers in the age range 18-48 y.Main outcome measures: Plasma flavonoids, ascorbic acid, tocopherols and caratenoids, plasma antioxidant capacity, lymphocyte DNA damage, blood chemistry and haematology, liver function tests, urinary malondialdehyde, 8-hydroxy-2-deoxyguanosine and 8-iso-prostaglandin F-2 alpha.Results: Eighteen volunteers completed the trial. Rutin supplementation did not induce any adverse changes in blood chemistry or indices of liver function. Plasma flavonoids were significantly elevated in the rutin-supplemented group. Endogenous oxidation of pyrimidines was significantly decreased in both rutin- and placebo-treated volunteers. There was no significant change in the level of urinary 8-hydroxy-2'-deoxyguanosine or urinary malondialdehyde in either group. A linear correlation was observed between urinary malondialdehyde and urinary 8-iso-prostaglandin F-2 alpha (R = 0.54, P < 0.01).Conclusion: Six weeks' rutin supplementation significantly elevated the levels of three plasma flavonoids (quercetin, kaempferol and isorhamnetin) but there was no significant change in plasma antioxidant status. The decrease in the level of endogenous base oxidation in lymphocyte DNA seen in bath the placeba- and rutin-supplemented subjects may reflect seasonal changes in other dietary antioxidants.",
keywords = "flavonoids, bioavailability, plasma antioxidant status, DNA damage, 8-iso-prostagiandin F-2 alpha, LOW-DENSITY-LIPOPROTEIN, CORONARY-HEART-DISEASE, PERFORMANCE LIQUID-CHROMATOGRAPHY, ARACHIDONIC-ACID METABOLISM, LIPID-PEROXIDATION, RED WINE, IN-VITRO, OXIDATIVE MODIFICATION, PHENOLIC SUBSTANCES, REDUCING ABILITY, 8-iso-prostagiandin F-2 alpha",
author = "Boyle, {S P} and Dobson, {V L} and Duthie, {Susan Joyce} and Hinselwood, {D C} and Janet Kyle and Collins, {A R}",
year = "2000",
month = "10",
language = "English",
volume = "54",
pages = "774--782",
journal = "European Journal of Clinical Nutrition",
issn = "0954-3007",
publisher = "NATURE PUBLISHING GROUP",
number = "10",

}

TY - JOUR

T1 - Bioavailability and efficiency of rutin as an antioxidant

T2 - a human supplementation study

AU - Boyle, S P

AU - Dobson, V L

AU - Duthie, Susan Joyce

AU - Hinselwood, D C

AU - Kyle, Janet

AU - Collins, A R

PY - 2000/10

Y1 - 2000/10

N2 - Objective: To determine the potential antioxidant effect of rutin (quercetin-3-O-beta-rutinoside) supplementation.Design: A 6-week randomized single-blind placebo controlled trial was conducted; 500 mg rutin supplement was compared to an equivalent amount of glucose placebo. In addition, a pharmacokinetic study was carried out.Setting: The Rowett Research Institute, Aberdeen, UK.Subjects: Eighteen healthy non-obese normocholesterolaemic female volunteers in the age range 18-48 y.Main outcome measures: Plasma flavonoids, ascorbic acid, tocopherols and caratenoids, plasma antioxidant capacity, lymphocyte DNA damage, blood chemistry and haematology, liver function tests, urinary malondialdehyde, 8-hydroxy-2-deoxyguanosine and 8-iso-prostaglandin F-2 alpha.Results: Eighteen volunteers completed the trial. Rutin supplementation did not induce any adverse changes in blood chemistry or indices of liver function. Plasma flavonoids were significantly elevated in the rutin-supplemented group. Endogenous oxidation of pyrimidines was significantly decreased in both rutin- and placebo-treated volunteers. There was no significant change in the level of urinary 8-hydroxy-2'-deoxyguanosine or urinary malondialdehyde in either group. A linear correlation was observed between urinary malondialdehyde and urinary 8-iso-prostaglandin F-2 alpha (R = 0.54, P < 0.01).Conclusion: Six weeks' rutin supplementation significantly elevated the levels of three plasma flavonoids (quercetin, kaempferol and isorhamnetin) but there was no significant change in plasma antioxidant status. The decrease in the level of endogenous base oxidation in lymphocyte DNA seen in bath the placeba- and rutin-supplemented subjects may reflect seasonal changes in other dietary antioxidants.

AB - Objective: To determine the potential antioxidant effect of rutin (quercetin-3-O-beta-rutinoside) supplementation.Design: A 6-week randomized single-blind placebo controlled trial was conducted; 500 mg rutin supplement was compared to an equivalent amount of glucose placebo. In addition, a pharmacokinetic study was carried out.Setting: The Rowett Research Institute, Aberdeen, UK.Subjects: Eighteen healthy non-obese normocholesterolaemic female volunteers in the age range 18-48 y.Main outcome measures: Plasma flavonoids, ascorbic acid, tocopherols and caratenoids, plasma antioxidant capacity, lymphocyte DNA damage, blood chemistry and haematology, liver function tests, urinary malondialdehyde, 8-hydroxy-2-deoxyguanosine and 8-iso-prostaglandin F-2 alpha.Results: Eighteen volunteers completed the trial. Rutin supplementation did not induce any adverse changes in blood chemistry or indices of liver function. Plasma flavonoids were significantly elevated in the rutin-supplemented group. Endogenous oxidation of pyrimidines was significantly decreased in both rutin- and placebo-treated volunteers. There was no significant change in the level of urinary 8-hydroxy-2'-deoxyguanosine or urinary malondialdehyde in either group. A linear correlation was observed between urinary malondialdehyde and urinary 8-iso-prostaglandin F-2 alpha (R = 0.54, P < 0.01).Conclusion: Six weeks' rutin supplementation significantly elevated the levels of three plasma flavonoids (quercetin, kaempferol and isorhamnetin) but there was no significant change in plasma antioxidant status. The decrease in the level of endogenous base oxidation in lymphocyte DNA seen in bath the placeba- and rutin-supplemented subjects may reflect seasonal changes in other dietary antioxidants.

KW - flavonoids

KW - bioavailability

KW - plasma antioxidant status

KW - DNA damage

KW - 8-iso-prostagiandin F-2 alpha

KW - LOW-DENSITY-LIPOPROTEIN

KW - CORONARY-HEART-DISEASE

KW - PERFORMANCE LIQUID-CHROMATOGRAPHY

KW - ARACHIDONIC-ACID METABOLISM

KW - LIPID-PEROXIDATION

KW - RED WINE

KW - IN-VITRO

KW - OXIDATIVE MODIFICATION

KW - PHENOLIC SUBSTANCES

KW - REDUCING ABILITY

KW - 8-iso-prostagiandin F-2 alpha

M3 - Article

VL - 54

SP - 774

EP - 782

JO - European Journal of Clinical Nutrition

JF - European Journal of Clinical Nutrition

SN - 0954-3007

IS - 10

ER -